Z20.828 Insurance Policy Changes

ICD-10 Z20.828 is officially defined as "Contact with and (suspected) exposure to other viral communicable diseases." code Z20.828 is referenced in 9 tracked payer policy changes from Aetna, Blue Cross & Blue Shield of Mississippi, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z20.828 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 10, 2026Medium impact
Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2026-10-07)
Aetna considers immune globulins medically necessary for hepatitis B, cytomegalovirus, Rho-D, rabies, varicella zoster, tetanus, vaccinia, botulism, hepatitis A, measles (rubeola) and rubella exposures or conditions, and considers all other indications experimental, investigational, or unproven. Each product has its own initial criteria, such as hepatitis B immune globulin for members who had contact with an individual diagnosed with hepatitis B virus, Rho-D immune globulin for unsensitized Rh-negative women at 24 to 28 weeks gestation unless the father is known to be Rh-negative, and varicella zoster immune globulin for high-risk individuals with significant exposure to varicella. Continuation of therapy for each product is considered medically necessary for all members, including new members, who meet all initial medical necessity criteria.
Aetna · Identified Oct 5, 2026Medium impact
HIV Testing (CPB 0542, reviewed 2026-08-28)
Aetna considers HIV testing medically necessary for screening persons for HIV infection according to the recommendations of the U.S. Preventive Services Task Force and the CDC, starting with an FDA-approved antigen/antibody combination immunoassay. Reactive specimens go to an FDA-approved HIV-1/HIV-2 antibody differentiation immunoassay and, when indicated, an FDA-approved HIV-1 nucleic acid test. Aetna does not cover home HIV test kits that do not require a physician's prescription under any plans.
Aetna · Identified Sep 29, 2026Medium impact
Orthopoxvirus Vaccines (CPB 0644, reviewed 2026-09-25)
Aetna considers pre-exposure smallpox vaccination medically necessary when public health authorities advise it, for research laboratory personnel who work with orthopoxviruses, clinical laboratory personnel performing orthopoxvirus diagnostic testing, designated response team members at risk for occupational exposure, and healthcare personnel who administer ACAM2000 or care for persons infected with orthopoxviruses. Booster doses are covered for persons with ongoing occupational exposure to orthopoxviruses in accordance with CDC recommendations, and post-exposure smallpox vaccination is covered for persons exposed or at high risk of exposure during a public health response. Mpox vaccination with JYNNEOS is medically necessary for pre-exposure use in listed higher-risk groups and for post-exposure use in persons with known or presumed mpox exposure, and routine smallpox vaccination of the general population is not recommended.
Aetna · Identified Aug 18, 2026Medium impact
HIV Testing (CPB 0542, reviewed 2025-11-26)
Aetna considers HIV testing medically necessary for screening according to the recommendations of the U.S. Preventive Services Task Force and the CDC. Initial testing uses an FDA-approved antigen/antibody combination immunoassay, and further testing follows only for reactive results. Aetna does not cover home HIV test kits that do not require a physician's prescription under any plan, including the Confide Home HIV Test and the Home Access HIV Test System.
Aetna · Identified Aug 15, 2026Medium impact
Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2025-12-23)
Reviewed 2025-12-23, Aetna Clinical Policy Bulletin 0544 covers immune globulin products for post-exposure prophylaxis and treatment, including hepatitis B, cytomegalovirus, Rho(D), rabies, varicella zoster, tetanus, measles, rubella, vaccinia, and botulism immune globulins. For each product the policy lists the indications it considers medically necessary and states that all other indications are experimental, investigational, or unproven. Continuation of therapy is considered medically necessary for all members, including new members, who meet the initial criteria. Immune globulin intramuscular injection (GamaSTAN) requires precertification.
Aetna · Identified Aug 12, 2026Medium impact
Orthopoxvirus Vaccines (CPB 0644, reviewed 2025-12-15)
Aetna considers orthopoxvirus vaccines medically necessary for the listed smallpox and mpox indications when the policy criteria are met, and routine smallpox vaccination of the general population is not recommended. Listed smallpox indications are pre-exposure vaccination for research laboratory personnel working with orthopoxviruses, clinical laboratory personnel performing diagnostic testing for orthopoxviruses, designated response team members at risk for occupational exposure, and healthcare personnel who administer ACAM2000 or care for persons infected with orthopoxviruses, along with JYNNEOS boosters for ongoing occupational exposure and post-exposure vaccination during a public health response. Listed mpox indications are pre-exposure vaccination for persons with known or presumed exposure to mpox virus or a sex partner diagnosed with mpox in the previous 14 days, and post-exposure JYNNEOS vaccination for persons with known or presumed exposure to mpox virus.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Coronavirus Disease 2019 (COVID-19) Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Testing
Blue Cross & Blue Shield of Mississippi covers FDA-approved COVID-19 RT-PCR testing using an upper respiratory specimen when it is medically appropriate for individuals with signs and symptoms compatible with COVID-19 without an alternative explanatory diagnosis. The same testing is medically appropriate for asymptomatic individuals with known or suspected recent exposure when their provider determines it is appropriate, and before elective surgeries and procedures involving the mouth, nose, oropharynx, nasopharynx, respiratory tract, gastrointestinal tract, or requiring general anesthesia or monitored anesthesia care (MAC). COVID-19 RT-PCR testing not approved by the FDA, including any test authorized under an EUA, is considered investigational, and FDA-approved testing performed for screening of asymptomatic individuals is considered not medically necessary. The policy was reviewed on 07/01/2026 with statements unchanged, and the code reference was updated to remove CPT codes 0240U and 0241U.
Colorado Medicaid · Identified Jun 20, 2026Medium impact
Health First Colorado (Colorado's Medicaid Program) News and Updates (B2200475 - 02/2022)
The February 2022 Health First Colorado provider bulletin (B2200475) covers several changes. Effective February 1, 2022, claims requiring electronic visit verification (EVV) go through pre-payment review, and claims without the needed EVV records may deny with EOB 3054. The bulletin also describes at-home OTC COVID-19 test billing under HCPCS E1399 with modifier U1 from January 15, 2022, requires the ordering provider's NPI on DMEPOS claims effective July 1, 2022, and notes that 24 physician-administered drug codes became subject to prior authorization effective January 18, 2022.
Blue Cross Blue Shield of Wyoming · Identified Jun 19, 2026Medium impact
NEW! Screening for COVID-19 Diagnosis Guidance
BCBS Wyoming has updated COVID-19 diagnostic testing coding guidance with new ICD-10 codes and clarified coverage rules. The policy specifies that asymptomatic and pre-surgical COVID-19 testing is covered when medically appropriate, but not for return-to-work or surveillance purposes.

Watch Z20.828

Get one email when a payer policy names Z20.828, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z20.828?

There are 9 tracked policy changes affecting code Z20.828, including updates from Aetna, Blue Cross & Blue Shield of Mississippi, Colorado Medicaid. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z20.828?

Payers that have issued tracked updates for code Z20.828 include: Aetna, Blue Cross & Blue Shield of Mississippi, Colorado Medicaid, Blue Cross Blue Shield of Wyoming.

How do I get notified when code Z20.828 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z20.828. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z20.828?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2026-10-07)

HIV Testing (CPB 0542, reviewed 2026-08-28)

Orthopoxvirus Vaccines (CPB 0644, reviewed 2026-09-25)

HIV Testing (CPB 0542, reviewed 2025-11-26)

Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2025-12-23)

Orthopoxvirus Vaccines (CPB 0644, reviewed 2025-12-15)

Coronavirus Disease 2019 (COVID-19) Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Testing

Health First Colorado (Colorado's Medicaid Program) News and Updates (B2200475 - 02/2022)

NEW! Screening for COVID-19 Diagnosis Guidance

What insurance policy changes affect code Z20.828?

Which payers have updated policy for code Z20.828?

How do I get notified when code Z20.828 policy changes?

Why do payers change policies for code Z20.828?